Drug Trial Radar · NCT07206043
Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Dec 3, 2024
Primary completion
Feb 27, 2025
Study completion Jul 25, 2025
Sponsor
- Lead sponsor
- R-Pharm International, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- LLC "Exacte Labs"; JSC "R-Pharm", Russia (R-Pharm Group)
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, immunogenicity and pharmacokinetics of RPH-104 after single intravenous and subcutaneous administration to healthy volunteers at different doses
Conditions
- Healthy
Interventions
RPH-104 80 mgBiological
solution for intravenous injection, 40 mg/mL
RPH-104 160 mgBiological
solution for intravenous injection, 40 mg/mL
RPH-104 320 mgBiological
solution for intravenous injection, 40 mg/mL
RPH-104 320 mgBiological
solution for subcutaneous injection, 80 mg/mL
RPH-104 80 mgBiological
solution for subcutaneous injection, 40 mg/mL
RPH-104 80 mgBiological
solution for subcutaneous injection, 80 mg/mL
PlaceboDrug
0.9% Sodium Chloride solution for Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The area under the plasma drug concentration-time curve (AUC) of RPH-104 from the moment of administration to infinity after a single injection of RPH-104Time frame: Up to day 61 ± 3
- The maximum concentration of RPH-104 in the blood serum after a single injection of RPH-104Time frame: Up to day 61 ± 3
- Percentage of volunteers (%) with AEs and SAEsTime frame: Up to day 61 ± 3
- Percentage of volunteers (%) with AEs ≥ Grade 3 according to CTCAE 5.0Time frame: Up to day 61 ± 3
- Percentage of volunteers (%) with ADRs and serious ADRsTime frame: Up to day 61 ± 3
- Percentage of volunteers (%) with ADRs ≥ Grade 3 according to CTCAE 5.0Time frame: Up to day 61 ± 3
- Percentage of volunteers (%), who prematurely discontinued participation in the study due to AE/SAE and ADR/serious ADRTime frame: Up to day 61 ± 3
- Percentage of volunteers (%) with AEs of special interestTime frame: Up to day 61 ± 3
- Percentage of volunteers (%), who developed binding antibodies to RPH-104Time frame: Up to day 61 ± 3
- Percentage of volunteers (%), who developed neutralizing antibodies to RPH-104Time frame: Up to day 61 ± 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Llc "Research Lab"
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.